SAN DIEGO, Jan. 23, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has established an Extracorporeal Therapy Scientific Advisory Board to guide the advancement of the Aethlon Hemopurifier® and other therapies developed from the Aethlon ADAPT™ system. Aethlon recently established a Scientific Advisory Board specific to Sepsis & Inflammation and during the course of 2012 expects to establish Science Advisory Boards comprised of thought leaders from the infectious disease and cancer community as well. Initial members of the Aethlon Extracorporeal Therapy Scientific Advisory Board include John Kellum, M.D., Gregory T. A. Kovacs, M.D., Ph.D., Nathan Levin, M.D., Hans Dietrich Polaschegg, Ph.D., Claudio Ronco, M.D., and David Ward, M.D.
"We are truly honored to have this esteemed group of industry thought leaders agree to provide their scientific insight to our therapeutic endeavors," stated Aethlon Chairman and CEO, Jim Joyce.
About Dr. Kellum
Dr. Kellum is a tenured professor of Critical Care Medicine at the University of Pittsburgh. He is a clinician scientist whose research interests span various aspects of Critical Care Medicine, but center in critical care nephrology (including acid-base, and renal replacement therapy), sepsis and multi-organ failure (including blood purification), and clinical epidemiology. His research has received continuous funding from the National Institutes of Health since 2001 and he has active funding from multiple different NIH Institutes. Dr. Kellum has authored more than 300 publications and has also edited several major textbooks including Crit
|SOURCE Aethlon Medical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved